Results 1 to 10 of about 331,825 (303)
Bladder CancerThe National Cancer Institute organized a virtual Clinical Trials Planning Meeting (CTPM) on ‘Defining the next generation of clinical trials with combination therapies in non-muscle invasive bladder cancer (NMIBC)’ led by the Bladder Cancer Task Force ...
Andrea Apolo +31 more
doaj +2 more sources
Bladder Cancer Molecular Taxonomy: Summary from a Consensus Meeting
Bladder Cancer, 2016 The advent of Omics technologies has been key to the molecular subclassification of urothelial bladder cancer. Several groups have used different strategies to this aim, with partially overlapping findings.
Seth P. Lerner +7 more
doaj +2 more sources
Urology, 1996 SummaryBladder cancer is the fourth most common cancer in England and Wales. The most common presenting symptom is macroscopic haematuria. The management options for superficial and invasive bladder cancer depend on the stage at presentation. Most superficial bladder cancers are managed by transurethral resection and cytoscopic follow-up. The prognosis
H Y, Leung, T R, Griffiths, D E, Neal
openaire +4 more sources
Current Treatment Options in Oncology, 2009 Bladder cancer is a complex disease of older patients with coexisting medical problems requiring multimodal therapy. For patients with localized bladder cancer, standard management for superficial disease includes transurethral resection with or without intravesical therapy, while muscle-invasive cancer is managed with neoadjuvant cisplatin- based ...
David J, Gallagher, Matthew I, Milowsky
+9 more sources
Frontiers in Surgery, 2022 IntroductionNon-muscle-invasive bladder cancer (NMIBC) is a common and heterogeneous disease; many patients develop recurrent or progress to muscle-invasive disease.
Kelly Ward +4 more
doaj +1 more source
Genome Medicine, 2022 Background Three-quarters of bladder cancer patients present with early-stage disease (non-muscle-invasive bladder cancer, NMIBC, UICC TNM stages Ta, T1 and Tis); however, most next-generation sequencing studies to date have concentrated on later-stage ...
Anshita Goel +16 more
doaj +1 more source
European Urology Open Science, 2022 Background: Mutations in STAG2 cause complete loss of STAG2 protein in approximately one-third of non–muscle-invasive bladder cancers (NMIBCs). STAG2 protein expression is easily determined via immunohistochemistry (IHC) and published data suggest that ...
Naheema S. Gordon +9 more
doaj +1 more source
The Scientific World JOURNAL, 2011 To review the epidemiology, diagnosis, and management of all stages of bladder cancer with an emphasis on studies published within the last year.Smoking continues to be the most important risk factor for the development of bladder cancer, and this risk has increased over time.
Todd M, Morgan +2 more
openaire +5 more sources
PD-L2 Is Constitutively Expressed in Normal and Malignant Urothelium
Frontiers in Oncology, 2021 The use of immune checkpoint blockade, in particular PD-1 and PD-L1 inhibitors, is now commonplace in many clinical settings including the treatment of muscle-invasive bladder cancer (MIBC).
Alexander C. Dowell +9 more
doaj +1 more source
JAMA, 2020 Bladder cancer is a common malignancy in women and is the fourth most common malignancy in men. Bladder cancer ranges from unaggressive and usually noninvasive tumors that recur and commit patients to long-term invasive surveillance, to aggressive and invasive tumors with high disease-specific mortality.Advanced age, male sex, and cigarette smoking ...
Andrew T, Lenis +2 more
openaire +4 more sources